Endometrial Cancer

Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.

Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.

The progression-free survival benefit of dostarlimab and chemotherapy extends to those with mismatch repair deficient or microsatellite instability–high advanced endometrial cancer.

Investigators report that loss of MMR mechanism is not predictive of response to chemotherapy or pembrolizumab in patients with stage III or IVA, stage IVB, or recurrent endometrial cancer.

Durvalumab plus olaparib, durvalumab monotherapy, or chemotherapy plus durvalumab saw an improvement in progression-free survival for patients with newly diagnosed advanced or recurrent endometrial cancer.

Treatment with dostarlimab plus chemotherapy followed by dostarlimab appears to improve outcomes among patients with advanced endometrial cancer and mismatch repair deficient disease in the phase 3 RUBY trial.

Data from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial support the use of frontline dostarlimab plus chemotherapy for dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Data from the phase 3 KEYNOTE-775 trial support lenvatinib plus pembrolizumab as a standard therapy option for patients with previously treated advanced endometrial cancer.

Data from the phase 3 RUBY trial may support the use of dostarlimab plus chemotherapy as a new standard of care in patients with newly diagnosed primary advanced or recurrent endometrial carcinoma.

Shannon N. Westin, MD, MPH, FACOG, presented results showing a progression-free survival response with combination durvalumab plus olaparib in newly diagnosed advanced or recurrent endometrial cancer.

Atezolizumab plus platinum chemotherapy showed significant improvement in progression-free survival for patients with frontline advanced or recurrent endometrial carcinoma.

Findings from a secondary data analysis suggest a need for further research to determine risk factors that place younger patients who are Puerto Rican at a high risk of endometrial cancer.

Findings from a meta-analysis support the feasibility of administering hysteroscopic surgery plus progesterone to patients of childbearing age with various types of endometrial cancer.

Data from a phase 1/2 trial support the fast track designation for tulmimetostat as a treatment for patients with ARID1A-mutated advanced, recurrent or metastatic endometrial cancer.

Findings suggest the presence of different genetic pathways that may drive disparities in outcomes between Black and White patients with endometrioid endometrial cancer, according to Kristin Taylor, MD.

Cutting out radiotherapy appears to be safe while improving quality of life in patients with POLE-mutated endometrial cancer.

Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.

Findings from the phase 3 RUBY trial support the FDA’s approval of dostarlimab/chemotherapy as a treatment for advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability–high.

A progression-free survival benefit was seen in those with TP53 wild-type advanced/recurrent endometrial cancer who were treated with selinexor maintenance regardless of microsatellite instability status.

The QPOLE assay may be a fast, low-cost alternative to other next-generation sequencing tools for POLE testing among patients with endometrial cancer.

Pembrolizumab plus chemotherapy may improve clinical outcomes over placebo among patients with advanced or recurrent endometrial cancer.

The FDA accepts a supplemental biologics license application for dostarlimab plus chemotherapy in the treatment of mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer based on data from a prespecified interim analysis of the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial.

Health-related quality of life data support dostarlimab plus chemotherapy as a standard of care in primary advanced or recurrent endometrial cancer, according to an expert from Copenhagen University Hospital in Denmark.

Dostarlimab produces a survival benefit vs placebo in combination with standard of care therapy regardless of whether patients had mismatch repair deficient/microsatellite instability-high disease.

Data from the phase 3 DUO-E trial indicate that the safety of durvalumab/chemotherapy with or without olaparib/durvalumab or durvalumab monotherapy maintenance in recurrent endometrial cancer was consistent with previous reports of each agent.